Table 1.
Baseline Demographic and Clinical Characteristics of Patients with VP4
| Number (N=41) | |
|---|---|
| Gender | |
| Female | 4 (9.8) |
| Male | 37 (90.2) |
| Age | n (%) |
| <65 | 36 (87.8) |
| ≥65 | 5 (12.2) |
| Child-Pugh | |
| A | 32 (78.0) |
| B | 9 (22.0) |
| ECOG-PS, score | |
| 0–1 | 39 (95.1) |
| 2 | 2 (4.9) |
| Platelet, (×109/L) | |
| <100 | 5 (12.2) |
| ≥100 | 36 (87.8) |
| Total bilirubin, µmol/L | |
| <34 | 38 (92.7) |
| ≥34 | 3 (7.3) |
| Albumin g/L | |
| <35 | 10 (24.4) |
| ≥35 | 31 (75.6) |
| ALT, IU/L | |
| <40 | 18 (43.9) |
| ≥40 | 23 (56.1) |
| AST, IU/L | |
| <40 | 8 (19.5) |
| ≥40 | 33 (80.5) |
| ALBI grade | |
| 1 | 12 (29.3) |
| 2 | 29 (70.7) |
| AFP, ng/mL | |
| <400 | 14 (34.1) |
| ≥400 | 27 (65.9) |
| Maximum tumor size, cm | |
| <5 | 4 (9.8) |
| ≥5 | 37 (90.2) |
| Anti-PD-1 antibodies | |
| Sintilimab | 15 (36.6) |
| Tislelizumab | 20 (48.8) |
| Camrelizumab | 6(14.6) |
| Tumor number | |
| Solitary | 10 (24.4) |
| Multiple | 31 (75.6) |
| Operation | |
| Yes | 12 (29.3) |
| No | 29 (70.7) |
| Extrahepatic metastases | |
| Yes | 3 (7.3) |
| No | 38 (92.7) |
| HBsAg | |
| Negative | 0 (0.00) |
| Positive | 41 (100.0) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; ALT, alanine transaminase; AST, aspartate transaminase; ALBI, albumin-bilirubin; AFP, ɑ-fetoprotein; HBsAg, hepatitis B surface antigen.